Acquired Point Mutations of TKD Are Responsible for Sorafenib Resistance in FLT3-ITD Mutant AML

被引：0
|
作者：
Zhang, Weiguo [1 ]
Konopleva, Marina [1 ]
Jacamo, Rodrigo O. [1 ]
Borthakur, Gautam
Chen, Wenjing
Cortes, Jorge E.
Ravandi, Farhad
Andreeff, Michael [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Sect Mol Hematol & Therapy, Dept Leukemia, Houston, TX 77030 USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
LEUKEMIA;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1495 / 1495
页数：1
相关论文
共 50 条
  • [31] Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo
    Christoph Rummelt
    Sivahari P. Gorantla
    Manja Meggendorfer
    Anne Charlet
    Cornelia Endres
    Konstanze Döhner
    Florian H. Heidel
    Thomas Fischer
    Torsten Haferlach
    Justus Duyster
    Nikolas von Bubnoff
    Leukemia, 2021, 35 : 2017 - 2029
  • [32] Inhibition of Menin, BCL-2, and FLT3 Combined with a Hypomethylating Agent Cures NPM1/FLT3-ITD/-TKD Mutant AML in a PDX Model
    Carter, Bing Z.
    Mak, Po Yee
    Tao, Wenjing
    Ostermann, Lauren B.
    Mak, Duncan
    Ke, Boazhen
    Ordentlich, Peter
    McGeehan, Gerard M.
    Andreeff, Michael
    BLOOD, 2022, 140 : 3063 - 3064
  • [33] Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo
    Rummelt, Christoph
    Gorantla, Sivahari P.
    Meggendorfer, Manja
    Charlet, Anne
    Endres, Cornelia
    Doehner, Konstanze
    Heidel, Florian H.
    Fischer, Thomas
    Haferlach, Torsten
    Duyster, Justus
    von Bubnoff, Nikolas
    LEUKEMIA, 2021, 35 (07) : 2017 - 2029
  • [34] Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo
    Rummelt, C.
    Gorantla, S. P.
    Endres, C.
    Doehner, K.
    Meggendorfer, M.
    Heidel, F.
    Fischer, T.
    Haferlach, T.
    Duyster, J.
    von Bubnoff, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 169 - 169
  • [35] Role of Autophagy in Resistance of FLT3-ITD AML Stem Cells to FLT3 TKI Treatment
    Qiu, Shaowei
    Yan, Chengcheng
    Paterson, Andrew J.
    Li, Hui
    Anderson, Nick
    Abraham, Ajay
    He, Jianbo
    Shah, Mansi
    Agarwal, Puneet
    Yang, Jing
    Xie, Min
    Lu, Rui
    Welner, Rob S.
    Bhatia, Ravi
    BLOOD, 2019, 134
  • [36] Proteasomal alterations in a newly created model of FLT3-ITD positive AML with acquired pan-TKI resistance
    Wilson, Katie
    Irwin, Mary E.
    Chandra, Joya
    CANCER RESEARCH, 2014, 74 (19)
  • [37] Phase I Trial of Maintenance Sorafenib after Allogeneic HSCT for Patients with FLT3-ITD AML
    Chen, Yi-Bin
    Li, Shuli
    Lane, Andrew A.
    Del Rio, Candice
    Connolly, Christine
    Ballen, Karen K.
    Cutler, Corey S.
    Dey, Bimalangshu R.
    Fathi, Amir T.
    Ho, Vincent T.
    Joyce, Amy
    McAfee, Steven L.
    Spitzer, Thomas R.
    Levis, Mark
    Soiffer, Robert J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (02) : S152 - S152
  • [38] Simultaneous Detection of FLT3-ITD, FLT3-D835 and NPM1 Mutations in AML
    Bernardino, L. P.
    Nagy, P. L.
    Hensel, J. W.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2008, 10 (06): : 578 - 578
  • [39] HYPOXIA REGULATES FLT3-ITD EXPRESSION AND FUNCTION IN AML CELL-LINES HARBOURING A FLT3-ITD MUTATION
    Sironi, S.
    Wagner, M.
    Vasold, J.
    Drolle, H.
    Fiegl, M.
    ANNALS OF HEMATOLOGY, 2013, 92 : S12 - S13
  • [40] Mechanism-Based Combinatorial Strategy for Overcoming FLT3-Inhibitor Resistance in Dual FLT3 ITD and TKD Point Mutations
    Ly, Charlie
    Zhang, Weiguo
    Ruvolo, Vivian
    Shah, Neil P.
    Andreeff, Michael
    BLOOD, 2016, 128 (22)
12345